Company intelligence

Liminatus Pharma

BiotechFullerton, California, USA

Is this your company? Get featured or correct your listing →

Suggest a correction

Recent changes

  1. Jun 23, 2026Cancer-Immunotherapy Developer Liminatus Pharma Files S-1 to Go Public Pulse story
  2. Jun 3, 2026Raised $1.9M SEC EDGAR Form D

Funding History

1 event · sources dated per row
DateEventAmountValuationInvestorsSource
Jun 3, 2026funding round$1.9M—
SEC EDGAR Form D

Latest Pulse

  1. Cancer-Immunotherapy Developer Liminatus Pharma Files S-1 to Go PublicLiminatus Pharma, a clinical-stage biotech developing cancer immunotherapies, filed a Form S-1 with the SEC for an IPO. The filing is a sign of life in the long-dormant biotech IPO market, which has lagged the tech-led reopening.→

Coverage Timeline

newest first
  1. Jun 23, 2026IPOCancer-Immunotherapy Developer Liminatus Pharma Files S-1 to Go PublicS-1 filed→

All Coverage

IPO

Cancer-Immunotherapy Developer Liminatus Pharma Files S-1 to Go Public

Illustration for: Cancer-Immunotherapy Developer Liminatus Pharma Files S-1 to Go Public
IPOS-1 filed

Cancer-Immunotherapy Developer Liminatus Pharma Files S-1 to Go Public

Liminatus Pharma, a clinical-stage biotech developing cancer immunotherapies, filed a Form S-1 with the SEC for an IPO. The filing is a sign of life in the long-dormant biotech IPO market, which has lagged the tech-led reopening.

Related Companies

Same sector
Scribe TherapeuticsAttovia TherapeuticsIambic TherapeuticsApnimedRetension PharmaceuticalsEli Lilly
Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction